A Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Rozanolixizumab in Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)

Status:
Enrolling by invitation

Trial end date:
2023-12-01

Target enrollment:

Participant gender:

The purpose of this study is to assess the long-term safety, tolerability and clinical efficacy of treatment with rozanolixizumab.

Phase 3

UCB Biopharma SRL

Rozanolixizumab